Q-omics provides the consensus-scored SLC9A2 profile across patient tissues and cancer cell-line models. SLC9A2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLC9A2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SLC9A2 RNA expression shows 16,204 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where SLC9A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC9A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC9A2 survival associations across molecular data types. SLC9A2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC9A2 RNA expression–survival associations across cancer types. High SLC9A2 expression shows unfavorable associations in LUAD, THCA, MESO and KIRP, but favorable associations in LGG and READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for SLC9A2 RNA expression.
This table summarizes SLC9A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SLC9A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC9A2 shows lower tumor expression in KIRC, COAD, KIRP and READ and higher tumor expression in LUSC and UCEC. The KIRC box plot shows higher SLC9A2 RNA expression in normal versus tumor tissue (log2 FC = −3.046, t-test p < 0.001).
This table shows molecular features associated with SLC9A2 in patient tissues and cancer cell lines. In patient samples, SLC9A2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC9A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
